The results are consistent with previous observations that hematological malignancies are not part of the clinical spectrum observed in these individuals16–18 and support the broader clinical findings that, despite the elevated genome-wide mutation rate, individuals with POLE and POLD1 mutations do not show an increased frequency of age-related phenotypes. The gene discussed is POLE; the disease is hematologic disorder.